BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BC Extra | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BC Week In Review | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said the moves will extend its cash runway through mid-2020 and allow it to fund an expansion study of...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
BC Week In Review | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

Compugen Ltd. (NASDAQ:CGEN) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate its first-in-class mAb COM701 plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors. COM701 targets new checkpoint target poliovirus receptor related immunoglobulin domain...
BC Innovations | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
BC Innovations | Jul 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma; colorectal cancer Cell culture and mouse studies suggest inhibiting PVR could help treat cancer. In patient tissue samples, tumor levels of PVR mRNA were higher than in the corresponding normal tissues. In...
Items per page:
1 - 10 of 70